BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 4, 2024
Breaking News: Healing a health divide (that’s long overdue)
See today's BioWorld Science
Home
» Hansoh scientists patent new crystalline salts of ABL1 inhibitors for leukemia
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cancer
Hansoh scientists patent new crystalline salts of ABL1 inhibitors for leukemia
Oct. 28, 2024
No Comments
Researchers at Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed crystalline salts of known tyrosine-protein kinase ABL1 (ABL) inhibitors reported to be useful for the treatment of leukemia.
BioWorld Science
Cancer
Patents